- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07376200
Enkelvoudige oplopende dosisstudie van HEC-151-injectie
Een fase I klinische studie die de veiligheid, verdraagbaarheid, farmacokinetische/farmacodynamische kenmerken van een enkele dosis HEC-151-injectie evalueert bij gezonde Chinese deelnemers in een single-center, gerandomiseerd, placebo (single-blind) en positieve controle (open-label) onderzoek
Evaluate the safety, tolerability, PK/PD and immunogenicity characteristics of a single subcutaneous HEC-151 Injection solution in healthy participants
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Chengyong Tang, Doctor
- Telefoonnummer: +8618983286980
- E-mail: 17235387@qq.com
Studie Locaties
-
-
Bishan
-
Chongqing, Bishan, China, 402760
- Werving
- No. 9, Shuangxing Avenue,, Bishan
-
Contact:
- Chengyong Tang, Doctor
- Telefoonnummer: 8618983286980
- E-mail: 17235387@qq.com
-
-
Chongqing Municipality
-
Bishan, Chongqing Municipality, China, 402760
- Nog niet aan het werven
- No. 9, Shuangxing Avenue,
-
Contact:
- Chengyong Tang, Doctor
- Telefoonnummer: +8618983286980
- E-mail: 17235387@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Voluntarily participate in the trial and sign the informed consent form, understanding and abiding by the research procedures;
- When signing the informed consent form, men aged 18-45 years old (including the boundary value) are eligible;
- During the screening process, male subjects with a body weight of ≥ 50 kg and a body mass index (BMI) of ≥ 19.0 and ≤ 24.0 kg/m2 are included;
- Normal glucose tolerance [3.9 mmol/L < fasting blood glucose (FPG) < 6.1 mmol/L, and 2-hour post-glucose tolerance test (OGTT) blood glucose after sugar intake < 7.8 mmol/L];
- Normal results of insulin release test (IRT), or abnormal results but judged by the researcher to have no clinical significance;
- Glycated hemoglobin (HbA1c) < 5.7%;
- During the study period, there are no plans for reproduction, sperm collection, or sperm donation, and are willing to take effective contraceptive measures throughout the study period until 3 months after the administration of the investigational drug.
Exclusion Criteria:
- Participants with abnormal medical histories or surgical histories judged clinically significant by the researchers, or currently suffering from any diseases in the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, etc. that are judged clinically significant by the researchers, or any other diseases or physiological conditions that can significantly affect the absorption, distribution, metabolism or excretion of the drugs;
- Participants who have a known severe allergic history or are allergic to the test drugs and any of their components;
- Participants who had severe trauma or undergone surgery within 90 days before the screening, or plan to undergo major surgery during the study;
- Participants who have a history of hypoglycemia or hyperglycemia within 90 days before the screening, or have a family history of diabetes (first-degree direct relatives);
- Participants who have donated blood or suffered significant blood loss (≥ 400 mL) within 90 days before the screening, or plan to donate blood during the study;
- Participants who have acute diseases or concurrent medication use from the signing of the informed consent form to the first administration of the drug;
- Participants whose vital signs, physical examination, laboratory tests, electrocardiogram, chest X-ray examination, etc. results are abnormal and judged by the researchers to have clinical significance;
- Participants whose test results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), combined human immunodeficiency virus antigen antibody (HIV), or syphilis spirochete antibody (TP) are positive;
- Participants who have a history of drug abuse or drug use, or whose urine drug screening is positive before the screening;
- Participants who have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, health supplements (except for regular supplementary vitamins and calcium) within 30 days before the screening;
- Participants who have participated in any clinical research of drugs or devices (defined as receiving the test drugs or devices) within 90 days before the screening;
- Participants who have received any vaccine within 30 days before the screening, or plan to receive any type of vaccine during the study;
- Participants who smoke more than 5 cigarettes per day within 90 days before the screening, or cannot comply with the smoking prohibition rule during the study;
- Participants who frequently drink alcohol, that is, consuming more than 14 units of alcohol per week (1 unit = 360 mL of beer or 45 mL of 40% alcohol spirits or 150 mL of wine), or have a positive alcohol breath test; or who cannot comply with the alcohol prohibition rule during the study;
- Participants who consume excessive tea, coffee and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 mL) or food (such as chocolate) every day within 90 days before the screening, or during the study;
- Participants who have used special diets (including dragon fruit, mango, pomelo, etc.) and/or xanthine diet (salmon, sardines, liver, kidney, etc.) or have other factors affecting drug absorption, distribution, metabolism, and excretion before the signing of the informed consent form to the use of the test drugs, or who cannot comply with the prohibition of eating during the study;
- Participants who have had significant changes in diet or exercise habits within 90 days before the screening, or have engaged in intense exercise before the signing of the informed consent form to the use of the test drugs, or cannot stop during the study;
- Participants who have difficulty in venous blood collection, or cannot tolerate venipuncture, or have a history of fainting or hematemesis;
- Participants who, in the researcher's opinion, have other factors that are not suitable for participating in this study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: HEC-151 Injection
The participants received an abdominal subcutaneous HEC-151 Injection in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Actieve vergelijker: Insulin Degludec
The participants received an abdominal subcutaneous injection of Insulin Degludec in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
|
Placebo-vergelijker: Placebo
The participants received an abdominal subcutaneous Injection of placebo in the morning of Day 1. |
Subcutaneous injection in the abdominal area |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Adverse event
Tijdsspanne: From Day1 to Day36
|
Frequency, type and severity of adverse events/serious adverse events. |
From Day1 to Day36
|
|
Electrocardiogram parameter(Heart rate)
Tijdsspanne: From Day1 to Day36
|
Evaluation the heart rate of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(PR interval)
Tijdsspanne: From Day1 to Day36
|
Evaluation the PR interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QTcF interval)
Tijdsspanne: From Day1 to Day36
|
Evaluation the QTcF interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Electrocardiogram parameter(QRS interval)
Tijdsspanne: From Day1 to Day36
|
Evaluation the QRS interval of electrocardiogram parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Body temperature)
Tijdsspanne: From Day1 to Day36
|
Evaluation the body temperature of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Blood pressure)
Tijdsspanne: From Day1 to Day36
|
Evaluation the blood pressure of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Pulse)
Tijdsspanne: From Day1 to Day36
|
Evaluation the pulse of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
|
Vital signs parameter(Respiration)
Tijdsspanne: From Day1 to Day36
|
Evaluation the respiration of vital signs parameters, and summarize the baseline data, post-administration data, and the changes from baseline after administration for each visit and treatment group. |
From Day1 to Day36
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cmax
Tijdsspanne: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUC0-t
Tijdsspanne: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
Tmax
Tijdsspanne: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
T1/2
Tijdsspanne: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
CL/F
Tijdsspanne: From Day1 to Day36
|
Evaluate the pharmacokinetic effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
GIRmax
Tijdsspanne: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
tGIRmax
Tijdsspanne: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
AUCGIR
Tijdsspanne: From Day1 to Day36
|
Evaluate the Pharmacodynamics effects of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
|
ADA(Anti-Drug Antibody)
Tijdsspanne: From Day1 to Day36
|
Evaluate the Immunogenic characteristics of HEC-151 Injection in healthy participants. |
From Day1 to Day36
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- HEC-151-DM-101
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .